Delcath Systems (NASDAQ:DCTH) Releases Earnings Results, Misses Expectations By $0.12 EPS

Posted by James Conley on Aug 6th, 2024

Delcath Systems (NASDAQ:DCTH – Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.12), RTT News reports. The firm had revenue of $7.77 million for the quarter, compared to the consensus estimate of $5.00 million. Delcath Systems had a negative net margin of 1,080.72% and a negative return on equity of 290.07%. During the same quarter in the prior year, the business posted ($0.58) earnings per share.

Delcath Systems Stock Performance

Shares of DCTH stock traded down $0.96 on Tuesday, reaching $7.36. The stock had a trading volume of 623,636 shares, compared to its average volume of 243,958. Delcath Systems has a 1 year low of $2.25 and a 1 year high of $9.18. The stock has a market cap of $204.50 million, a P/E ratio of -2.91 and a beta of 0.64. The company has a 50 day simple moving average of $7.81 and a 200 day simple moving average of $5.99.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on DCTH. HC Wainwright reissued a “buy” rating and set a $22.00 price target on shares of Delcath Systems in a research report on Tuesday. Craig Hallum started coverage on Delcath Systems in a report on Friday, June 28th. They issued a “buy” rating and a $18.00 target price for the company. Finally, Stephens reaffirmed an “overweight” rating and set a $25.00 price target on shares of Delcath Systems in a report on Tuesday. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $19.83.

Check Out Our Latest Research Report on DCTH

Delcath Systems Company Profile

(Get Free Report)

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.